SKYRIZI REAL
PATIENT STORIES

MARIANN: My name is Mariann, and I have moderate to severe UC.

SUPER: MARIANN
A REAL ULCERATIVE COLITIS PATIENT

MARIANN: My doctor put me on a treatment after I was diagnosed, but I was still having uncontrolled symptoms.

MARIANN: It was many, many bathroom trips during the day.

MARIANN: I was still bleeding.

MARIANN: And I was satisfied with that because it was so much better than where I had been.

MARIANN: The partnership with the doctor was invaluable.

MARIANN: Each time I would see the doctor, I would go in all excited because, in my mind, I had improved, and I wanted to improve, because my goal is remission.

SUPER: My goal is REMISSION

MARIANN: And then she would do the colonoscopy and have to come out and say, “But you don’t look any better.”

MARIANN: And so that was also a big thing that finally hit home, that even though on the outside I’m thinking things are going along, my body really isn’t responding to the current drug.

MARIANN: And she felt that by switching to SKYRIZI that I could see improvement in the lining of my colon.

GRAPHIC: SKYRIZI Logo

LEGAL SUPER: SKYRIZI is a prescription medicine used to treat moderate to severe ulcerative colitis in adults. In clinical trials, SKYRIZI helped achieve visible colon lining repair at 12 weeks and 1 year. Areas that were visually assessed may not represent repair of the entire colon lining.

MARIANN: My doctor and I talked about the benefits and risks of SKYRIZI. 

LEGAL SUPER: Please see Important Safety Information near the end of this video.

MARIANN: After four weeks of SKYRIZI, I had fewer trips to the bathroom. I had less bleeding. 

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve significant symptom relief, including fewer bowel movements and bloody stools, as early as 4 weeks.

MARIANN: The first colonoscopy after SKYRIZI, the doctor came in and told me that I had visible colon lining repair, and that was the first time that she had been able to say that.

SUPER: I had visible COLON LINING REPAIR

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve visible colon lining repair at 12 weeks and 1 year. Areas that were visually assessed may not represent repair of the entire colon lining.

MARIANN: It was the best news in the world. I gave her a big hug and couldn’t wait to share the news with everybody.

MARIANN: At a recent appointment, my doctor confirmed I was in remission.

SUPER: My doctor confirmed I WAS IN REMISSION

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve remission at 12 weeks and 1 year.

MARIANN: Now that my symptoms are under control with SKYRIZI, an evening out could be anything. It could be going out to dinner with friends. It could be going out to a concert.

MARIANN: So from this point on, my goal is staying in remission and just living the life of retirement.

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve remission at 12 weeks and 1 year.

GRAPHIC: SKYRIZI Logo

LEGAL SUPER: Please keep watching for Important Safety Information.

VO/SUPER:

USE AND IMPORTANT SAFETY INFORMATION

SKYRIZI^® (risankizumab-rzaa) USE

SKYRIZI is a prescription medicine used to treat moderate to severe ulcerative colitis in adults.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI^® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

• Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
  • fainting, dizziness, feeling lightheaded (low blood pressure)
  • swelling of your face, eyelids, lips, mouth, tongue, or throat
  • trouble breathing or throat tightness
  • chest tightness
  • skin rash, hives
  • itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

• Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
  • fever, sweats, or chills
  • cough
  • shortness of breath
  • blood in your mucus (phlegm)
  • muscle aches
  • warm, red, or painful skin or sores on your body different from your psoriasis
  • weight loss
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”
• have an infection that does not go away or that keeps coming back.
• have TB or have been in close contact with someone with TB.
• have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
• are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
• become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important information I should know about SKYRIZI?”

Liver problems may happen while being treated for Crohn’s disease or ulcerative colitis: A person with Crohn’s disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn’s disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI (risankizumab-rzaa) is available in a 600 mg/10 mL vial for intravenous infusion and a 180 mg /1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

© 2025 AbbVie. All rights reserved.

SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd.

US-SKZG-250042